Drug Profile
Research programme: anthracyclines - Galilaeus Oy
Alternative Names: Research programme: anticancer therapeutics - Galilaeus Oy/Heidelberg Pharma Research; S 2512; S 2513Latest Information Update: 13 Oct 2017
Price :
$50
*
At a glance
- Originator Galilaeus Oy
- Developer Heidelberg Pharma
- Class Anthracyclines
- Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
- 15 May 2003 S 2513 and S 2521 are available for licensing (http://www.galilaeus.fi)
- 15 May 2003 Preclinical trials in Cancer in Finland (unspecified route)